Key result
β-blocker therapy at discharge was associated with a significantly lower risk of all-cause death in patients with acute coronary syndrome undergoing PCI (HR 0.33; 95% CI 0.17-0.65; P=0.001).
Why the study?
Does β-blocker therapy at discharge reduce all-cause death in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Population
3,180 patients with acute coronary syndrome undergoing successful percutaneous coronary intervention
Comparison
β-blocker therapy at discharge vs No β-blocker therapy at discharge
Design
Cohort
Authors
Loading...
May support β-blocker discharge therapy in ACS post-PCI; leaves open confirmation in randomized trials.
Cohort (n=3,180)
Does β-blocker therapy at discharge reduce all-cause death in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Hazard Ratio: 0.33 (95% CI 0.17–0.65)
p-value: p=0.001
Beta-blocker therapy at discharge, particularly at doses <50% of target, is associated with significantly reduced all-cause mortality in patients with ACS following successful PCI, with the greatest benefit observed in NSTEMI patients.
Li et al. (2016) conducted a cohort in Acute coronary syndrome undergoing percutaneous coronary intervention (n=3,180). β-blocker therapy at discharge vs. No β-blocker therapy was evaluated on All-cause death (HR 0.33, 95% CI 0.17-0.65, p=0.001). β-blocker therapy at discharge was associated with a significantly lower risk of all-cause death in patients with acute coronary syndrome undergoing PCI (HR 0.33; 95% CI 0.17-0.65; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: